<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394561</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457AIT01</org_study_id>
    <nct_id>NCT02394561</nct_id>
  </id_info>
  <brief_title>A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)</brief_title>
  <acronym>SUPREME</acronym>
  <official_title>A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the differences in the efficacy and safety of secukinumab between
      Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biological agents represent the most advanced type of treatment for psoriasis. Secukinumab is
      a human monoclonal anti IL-17A antibody that binds to human IL-17A and neutralizes its
      bioactivity by inhibiting IL17A produced by both Th17 cells and those of the innate immune
      system, thus providing complete anti IL17A blockage. Targeting IL-17A has the potential to
      reduce autoimmune inflammation while leaving other immune functions undisturbed. While
      targeting of Th1-promoting or Th17-promoting cytokines affects critical mediators such as
      IFN-γ, IL-22 and IL-21, selective targeting of IL-17A leaves these Th1/17 activities, as well
      as certain protective functions of innate cells intact. Furthermore, as a fully human
      monoclonal antibody, secukinumab should reduce immunogenic risks compared to current or
      emerging antibody therapies that are not fully human.

      Many recent studies have shown that highly selective biologic drugs are not effective in
      every patient and that variations in the genome can be associated with different clinical
      responses or side effects to a given drug. The PSORS1 locus on chromosome 6p is generally
      understood to confer the most risk for psoriasis. A specific allele for this locus, HLA C*06,
      is present in about 60% of psoriatic patient cases. Data linking secukinumab efficacy to a
      particular genetic marker are lacking.

      Recent research has revealed a marked difference in the proportion of PASI 90 achievers at 12
      weeks between Cw6-positive and Cw6-negative patients (85.7% vs 56.5%) treated with
      ustekinumab (Talamonti M et al. 2013) and a greater efficacy of anti-TNFα drugs in CW6
      negative patients (Galli et al. 2013).Unlike anti-IL-12/23 agents, secukinumab inhibits IL-17
      produced by both Th17 cells after presentation by antigen presenting cells (in this case Cw6)
      and cells of the innate immune system whose activation does not require antigen presentation.
      Providing a drug that is equally effective on both Cw6-negative and Cw6-positive patients
      would be an important clinical accomplishment and would eliminate the need for costly HLA-Cw6
      tests. The choice of a cohort study would therefore seem appropriate for this clinical
      context.

      The purpose of this study was to explore the different efficacy and safety profile of
      secukinumab 300 mg in patients with moderate to severe chronic plaque-type psoriasis,
      stratified for the presence of HLA-C*06, whose determination was blinded for patients and
      investigators. The study was conducted both on anti-TNFα-naïve and anti-TNFα failure patients
      and also stratified for TNFα - 308 polymorphism, BMI, smoking and metabolic syndrome, among
      others.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2015</start_date>
  <completion_date type="Actual">June 8, 2017</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arms represent stratification of Cw6 positive and Cw6 negative patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage (%) of Patients Who Reach Psoriasis Area Severity Index (PASI) 90 at 16 Weeks - LOCF Approach (ITT Set)</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>PASI (Langley et al 2015) combines the assessment of the severity of lesions and the area affected into a single score with a range of 0 (no disease) to 72 (maximal disease). The PASI was assessed at all visits in CORE and extension phases. PASI 90 response: patients achieving ≥ 90% improvement (reduction) in PASI score compared to baseline are defined as PASI 90 responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of Patients With IGA 0/1, PASI 50, PASI 75, PASI 90, PASI 100 Responders by Visit - LOCF Approach (ITT Set)</measure>
    <time_frame>Baseline up to approximately 72 weeks</time_frame>
    <description>IGA mod 2011 scale measures severity of the psoriasis on a five-point scale ranging from 0 (no disease, 'clear') to 4 ('very severe'). PASI 50,75,90,100 represent: patients achieving ≥ 50% improvement (reduction) in PASI score compared to baseline, ≥ 75% improvement (reduction), ≥ 90% improvement (reduction) and PASI 100 response/remission: complete clearing of psoriasis (PASI=0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Mean Changes From Baseline in IGA Mod 2011 Between Cohorts at Each Time Point (LOCF) (ITT)</measure>
    <time_frame>Baseline up to approximately 72 weeks</time_frame>
    <description>IGA mod 2011 scale measures severity of the psoriasis on a five-point scale ranging from 0 (no disease, 'clear') to 4 ('very severe').</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Reach PASI 90 and 75 (ITT)</measure>
    <time_frame>Baseline up to approximately 72 weeks</time_frame>
    <description>Time in days to reach PASI scores of 90 and 75.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Dermatology Life Quality Index (DLQI) (LOCF) (FAS)</measure>
    <time_frame>Baseline up to approximatly 72 weeks</time_frame>
    <description>The DLQI total score was calculated by summing the score of each domain resulting in a maximum of 30 and a minimum of 0. The higher the score, the more Quality of Life was impaired. Meaning of DLQI Scores: 0-1 = no effect at all on patient's life, 2-5 = small effect on patient's life, 6-10 = moderate effect on patient's life, 11-20= very large effect on patient's life, 21-30 = extremely large effect on patient's life. It was pre-specified that results would be presented for all patients, not by cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Scores of HAD-A and HAD-D (Anxiety and Depression) (LOCF) (FAS)</measure>
    <time_frame>Baseline up approximately 72 weeks</time_frame>
    <description>The Hospital Anxiety and Depression Scale (HADS) is a fourteen-item scale.. Seven of the items relate to anxiety and seven relate to depression. This outcome measure was specifically developed to avoid reliance on aspects of these conditions that are also common somatic symptoms of illness, for example fatigue and insomnia or hypersomnia. Calculations of scores: each of the 14 items was rated on a 4-point scale. All items except 7 and 10 were scored as Yes, definitely = 3, Yes, sometimes = 2, No, not much = 1, to No, not at all = 0. Items 7 and 10 were scored as Yes, definitely = 0 to No, not at all = 3 in the reverse order. The HADS consisted of two sub-scores: the HAD-A (anxiety) and HAD-D (depression); each sub-score ranged from 0 to 21 points; scores ≥11 = presence of anxious or depressive disorders; scores between 8-10 points = borderline abnormal, and scores of ≤7 = disorder was not present. It was pre-specified that results would be presented for all patients, not by cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between the Hospital Anxiety and Depression Scale (HADS) and PASI (FAS)</measure>
    <time_frame>Baseline up to approximately 72 weeks</time_frame>
    <description>PASI score, HADS questionnaire correlation using Spearman rank correlation coefficient. It was pre-specified that results would be presented for all patients, not by cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Body Mass Index (Safety Set)</measure>
    <time_frame>Baseline up to approximately 72 weeks</time_frame>
    <description>Change in Body mass index from baseline for patients with a value at baseline and the respective post-baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Waist Circumference (Safety Set)</measure>
    <time_frame>Baseline up to approximately 72 weeks</time_frame>
    <description>Change in waist circumference from baseline for patients with a value at baseline and the respective post-baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Weight (Safety Set)</measure>
    <time_frame>Baseline up to approximately 72 weeks</time_frame>
    <description>Change in weight from baseline for patients with a value at baseline and the respective post-baseline visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">434</enrollment>
  <condition>Plaque Type Psorisis</condition>
  <arm_group>
    <arm_group_label>Cw6-positive AIN457 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cw6-negative AIN457 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection</description>
    <arm_group_label>Cw6-negative AIN457 300 mg</arm_group_label>
    <arm_group_label>Cw6-positive AIN457 300 mg</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have been able to understand and communicate with the investigator and to
             comply with the requirements of the study and must have given a written, signed and
             dated informed consent before any study related activity was performed.

          2. Men or women at least 18 years of age at time of screening.

          3. Diagnosis of moderate to severe chronic plaque-type psoriasis for at least 6 months
             (including concomitant psoriatic arthritis as per the Classification Criteria for
             Psoriatic Arthritis criteria [CASPAR]).

          4. Moderate to severe psoriasis as defined at enrollment by:

               -  PASI score ≥ 10 or

               -  PASI score &gt; 5 but &lt; 10 and DLQI ≥10

          5. Patients that are candidates for systemic therapy, whether treatment naïve or after
             failed response to other systemic therapy (i.e. cyclosporine, methotrexate and PUVA)
             or to an anti-TNFα (or is intolerant and/or has a contraindication to these).

        Exclusion criteria

          1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and
             guttate psoriasis).

          2. Cyclosporine or methotrexate therapy within 4 weeks prior to Day 1.

          3. Anti-TNFα therapy within timelines depending on drug half-life.

          4. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17
             or the IL-17 receptor.

          5. Previous exposure to ustekinumab or any other biologic drug for the treatment of
             psoriasis that was not anti-TNFα therapy.

          6. Intravenous or intramuscular steroids within 2 weeks prior to screening and during
             screening.

          7. Ongoing use of corticosteroid topical treatments or UV therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>(mi)</state>
        <zip>20161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>L'Aquila</city>
        <state>AQ</state>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brindisi</city>
        <state>BR</state>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chieti</city>
        <state>CH</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grosseto</city>
        <state>GR</state>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terracina</city>
        <state>LT</state>
        <zip>04019</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucca</city>
        <state>LU</state>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Macerata</city>
        <state>MC</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mantova</city>
        <state>MN</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erice</city>
        <state>TP</state>
        <zip>91016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <results_first_submitted>June 7, 2018</results_first_submitted>
  <results_first_submitted_qc>April 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>April 21, 2019</last_update_submitted>
  <last_update_submitted_qc>April 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02394561/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02394561/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Five hundred thirty participants were screened and 434 entered the CORE Phase. However, there were 3 patients without Cw6 assessment which was necessary for stratification to the two arms, therefore 431 were considered enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cw6-positive AIN457 300 mg</title>
          <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
        </group>
        <group group_id="P2">
          <title>Cw6-negative AIN457 300 mg</title>
          <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>CORE Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT Set</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cw6-positive AIN457 300 mg</title>
          <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
        </group>
        <group group_id="B2">
          <title>Cw6-negative AIN457 300 mg</title>
          <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="185"/>
            <count group_id="B2" value="246"/>
            <count group_id="B3" value="431"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.71" spread="13.148"/>
                    <measurement group_id="B2" value="47.18" spread="12.919"/>
                    <measurement group_id="B3" value="45.26" spread="13.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="241"/>
                    <measurement group_id="B3" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since first diagnosis of psoriasis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.63" spread="12.489"/>
                    <measurement group_id="B2" value="17.46" spread="11.343"/>
                    <measurement group_id="B3" value="18.39" spread="11.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage (%) of Patients Who Reach Psoriasis Area Severity Index (PASI) 90 at 16 Weeks - LOCF Approach (ITT Set)</title>
        <description>PASI (Langley et al 2015) combines the assessment of the severity of lesions and the area affected into a single score with a range of 0 (no disease) to 72 (maximal disease). The PASI was assessed at all visits in CORE and extension phases. PASI 90 response: patients achieving ≥ 90% improvement (reduction) in PASI score compared to baseline are defined as PASI 90 responders.</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cw6-positive AIN457 300 mg</title>
            <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cw6-negative AIN457 300 mg</title>
            <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (%) of Patients Who Reach Psoriasis Area Severity Index (PASI) 90 at 16 Weeks - LOCF Approach (ITT Set)</title>
          <description>PASI (Langley et al 2015) combines the assessment of the severity of lesions and the area affected into a single score with a range of 0 (no disease) to 72 (maximal disease). The PASI was assessed at all visits in CORE and extension phases. PASI 90 response: patients achieving ≥ 90% improvement (reduction) in PASI score compared to baseline are defined as PASI 90 responders.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" lower_limit="74.0" upper_limit="85.9"/>
                    <measurement group_id="O2" value="81.7" lower_limit="76.3" upper_limit="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The difference in percentage of patients achieving PASI 90 response between the Cw6-positive cohort and the Cw6-negative cohort was H0 = Cw6-positive minus Cw6-negative ≥0.12 and HA = Cw6-positive minus Cw6-negative was &lt; 0.12. The percentage of PASI 90 response by cohort as well as the difference between cohort together with 97.5% upper CI was provided using Clopper Pearson CI method.</non_inferiority_desc>
            <param_type>difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (%) of Patients With IGA 0/1, PASI 50, PASI 75, PASI 90, PASI 100 Responders by Visit - LOCF Approach (ITT Set)</title>
        <description>IGA mod 2011 scale measures severity of the psoriasis on a five-point scale ranging from 0 (no disease, 'clear') to 4 ('very severe'). PASI 50,75,90,100 represent: patients achieving ≥ 50% improvement (reduction) in PASI score compared to baseline, ≥ 75% improvement (reduction), ≥ 90% improvement (reduction) and PASI 100 response/remission: complete clearing of psoriasis (PASI=0).</description>
        <time_frame>Baseline up to approximately 72 weeks</time_frame>
        <population>Number of patients varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Cw6-positive AIN457 300 mg</title>
            <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cw6-negative AIN457 300 mg</title>
            <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
          <group group_id="O3">
            <title>Difference in % (Cw6-pos vs Cw6-neg)</title>
            <description>Difference in percentages of the two cohorts in IGA 0/1 and PASI 50, 75, 90,100 at all time points.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (%) of Patients With IGA 0/1, PASI 50, PASI 75, PASI 90, PASI 100 Responders by Visit - LOCF Approach (ITT Set)</title>
          <description>IGA mod 2011 scale measures severity of the psoriasis on a five-point scale ranging from 0 (no disease, 'clear') to 4 ('very severe'). PASI 50,75,90,100 represent: patients achieving ≥ 50% improvement (reduction) in PASI score compared to baseline, ≥ 75% improvement (reduction), ≥ 90% improvement (reduction) and PASI 100 response/remission: complete clearing of psoriasis (PASI=0).</description>
          <population>Number of patients varied across visits</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>W1 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="240"/>
                    <count group_id="O3" value="418"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.62" upper_limit="5.65"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.68" upper_limit="4.79"/>
                    <measurement group_id="O3" value="0.16" lower_limit="-2.86" upper_limit="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W1 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="240"/>
                    <count group_id="O3" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="8.78" upper_limit="19.29"/>
                    <measurement group_id="O2" value="12.1" lower_limit="8.24" upper_limit="16.89"/>
                    <measurement group_id="O3" value="1.32" lower_limit="-5.02" upper_limit="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W1 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="240"/>
                    <count group_id="O3" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.61" upper_limit="5.62"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.01" upper_limit="2.30"/>
                    <measurement group_id="O3" value="1.82" lower_limit="-0.52" upper_limit="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W2 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="5.05" upper_limit="13.74"/>
                    <measurement group_id="O2" value="6.9" lower_limit="4.08" upper_limit="10.83"/>
                    <measurement group_id="O3" value="1.79" lower_limit="-3.29" upper_limit="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W2 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="245"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="36.73" upper_limit="51.51"/>
                    <measurement group_id="O2" value="44.5" lower_limit="38.16" upper_limit="50.95"/>
                    <measurement group_id="O3" value="-0.47" lower_limit="-9.84" upper_limit="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W2 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="245"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="10.82" upper_limit="21.84"/>
                    <measurement group_id="O2" value="10.2" lower_limit="6.71" upper_limit="14.69"/>
                    <measurement group_id="O3" value="5.56" lower_limit="-0.80" upper_limit="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W2 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="245"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="1.21" upper_limit="6.96"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.90" upper_limit="5.25"/>
                    <measurement group_id="O3" value="0.81" lower_limit="-2.49" upper_limit="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W2 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="245"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.01" upper_limit="2.99"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.01" upper_limit="2.25"/>
                    <measurement group_id="O3" value="0.14" lower_limit="-1.78" upper_limit="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W3 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="18.43" upper_limit="31.32"/>
                    <measurement group_id="O2" value="21.1" lower_limit="16.21" upper_limit="26.78"/>
                    <measurement group_id="O3" value="3.32" lower_limit="-4.58" upper_limit="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W3 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="245"/>
                    <count group_id="O3" value="429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" lower_limit="69.26" upper_limit="82.06"/>
                    <measurement group_id="O2" value="71.8" lower_limit="65.76" upper_limit="77.38"/>
                    <measurement group_id="O3" value="4.25" lower_limit="-4.23" upper_limit="12.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W3 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="245"/>
                    <count group_id="O3" value="429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" lower_limit="31.52" upper_limit="46.03"/>
                    <measurement group_id="O2" value="34.3" lower_limit="28.36" upper_limit="40.60"/>
                    <measurement group_id="O3" value="4.30" lower_limit="-4.81" upper_limit="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W3 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="245"/>
                    <count group_id="O3" value="429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="8.54" upper_limit="18.78"/>
                    <measurement group_id="O2" value="11.4" lower_limit="7.73" upper_limit="16.09"/>
                    <measurement group_id="O3" value="1.61" lower_limit="-4.55" upper_limit="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W3 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="245"/>
                    <count group_id="O3" value="429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.89" upper_limit="6.23"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.90" upper_limit="5.25"/>
                    <measurement group_id="O3" value="0.27" lower_limit="-2.92" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" lower_limit="35.15" upper_limit="49.88"/>
                    <measurement group_id="O2" value="39.8" lower_limit="33.67" upper_limit="46.25"/>
                    <measurement group_id="O3" value="2.55" lower_limit="-6.75" upper_limit="11.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="81.84" upper_limit="91.91"/>
                    <measurement group_id="O2" value="87.4" lower_limit="82.59" upper_limit="91.27"/>
                    <measurement group_id="O3" value="0.10" lower_limit="-6.51" upper_limit="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" lower_limit="53.97" upper_limit="68.48"/>
                    <measurement group_id="O2" value="57.3" lower_limit="50.88" upper_limit="63.58"/>
                    <measurement group_id="O3" value="4.10" lower_limit="-5.29" upper_limit="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="21.39" upper_limit="34.78"/>
                    <measurement group_id="O2" value="22.0" lower_limit="16.94" upper_limit="27.65"/>
                    <measurement group_id="O3" value="5.77" lower_limit="-2.40" upper_limit="14.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="6.33" upper_limit="15.66"/>
                    <measurement group_id="O2" value="9.8" lower_limit="6.35" upper_limit="14.17"/>
                    <measurement group_id="O3" value="0.57" lower_limit="-5.09" upper_limit="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W8 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" lower_limit="65.22" upper_limit="78.61"/>
                    <measurement group_id="O2" value="73.2" lower_limit="67.17" upper_limit="78.60"/>
                    <measurement group_id="O3" value="-0.89" lower_limit="-9.48" upper_limit="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W8 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="91.61" upper_limit="98.10"/>
                    <measurement group_id="O2" value="95.1" lower_limit="91.63" upper_limit="97.45"/>
                    <measurement group_id="O3" value="0.53" lower_limit="-3.97" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W8 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" lower_limit="78.76" upper_limit="89.64"/>
                    <measurement group_id="O2" value="85.0" lower_limit="79.87" upper_limit="89.18"/>
                    <measurement group_id="O3" value="-0.18" lower_limit="-7.26" upper_limit="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W8 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" lower_limit="53.97" upper_limit="68.48"/>
                    <measurement group_id="O2" value="60.6" lower_limit="54.16" upper_limit="66.72"/>
                    <measurement group_id="O3" value="0.84" lower_limit="-8.46" upper_limit="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W8 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" lower_limit="27.93" upper_limit="42.14"/>
                    <measurement group_id="O2" value="34.6" lower_limit="28.63" upper_limit="40.86"/>
                    <measurement group_id="O3" value="0.23" lower_limit="-8.72" upper_limit="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK12 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="74.55" upper_limit="86.38"/>
                    <measurement group_id="O2" value="81.7" lower_limit="76.30" upper_limit="86.33"/>
                    <measurement group_id="O3" value="-0.73" lower_limit="-8.36" upper_limit="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK12 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="93.77" upper_limit="99.11"/>
                    <measurement group_id="O2" value="97.2" lower_limit="94.23" upper_limit="98.85"/>
                    <measurement group_id="O3" value="0.13" lower_limit="-3.65" upper_limit="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK12 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="88.22" upper_limit="96.18"/>
                    <measurement group_id="O2" value="90.7" lower_limit="86.30" upper_limit="93.98"/>
                    <measurement group_id="O3" value="2.28" lower_limit="-3.27" upper_limit="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK12 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" lower_limit="65.79" upper_limit="79.11"/>
                    <measurement group_id="O2" value="73.6" lower_limit="67.60" upper_limit="78.98"/>
                    <measurement group_id="O3" value="-0.75" lower_limit="-9.30" upper_limit="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK12 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" lower_limit="42.02" upper_limit="56.91"/>
                    <measurement group_id="O2" value="43.9" lower_limit="37.60" upper_limit="50.35"/>
                    <measurement group_id="O3" value="5.55" lower_limit="-3.93" upper_limit="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK16 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" lower_limit="79.37" upper_limit="90.10"/>
                    <measurement group_id="O2" value="86.2" lower_limit="81.23" upper_limit="90.23"/>
                    <measurement group_id="O3" value="-0.85" lower_limit="-7.79" upper_limit="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK16 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="94.53" upper_limit="99.40"/>
                    <measurement group_id="O2" value="98.8" lower_limit="96.48" upper_limit="99.75"/>
                    <measurement group_id="O3" value="-0.95" lower_limit="-4.33" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK16 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" lower_limit="89.56" upper_limit="96.98"/>
                    <measurement group_id="O2" value="93.1" lower_limit="89.17" upper_limit="95.92"/>
                    <measurement group_id="O3" value="0.93" lower_limit="-4.16" upper_limit="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK16 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" lower_limit="73.96" upper_limit="85.90"/>
                    <measurement group_id="O2" value="81.7" lower_limit="76.30" upper_limit="86.33"/>
                    <measurement group_id="O3" value="-1.27" lower_limit="-8.94" upper_limit="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK16 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" lower_limit="51.77" upper_limit="66.41"/>
                    <measurement group_id="O2" value="53.3" lower_limit="46.81" upper_limit="59.62"/>
                    <measurement group_id="O3" value="5.99" lower_limit="-3.49" upper_limit="15.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK20 IGA0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="81.22" upper_limit="91.46"/>
                    <measurement group_id="O2" value="87.4" lower_limit="82.59" upper_limit="91.27"/>
                    <measurement group_id="O3" value="-0.44" lower_limit="-7.11" upper_limit="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK20 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="94.53" upper_limit="99.40"/>
                    <measurement group_id="O2" value="97.6" lower_limit="94.77" upper_limit="99.10"/>
                    <measurement group_id="O3" value="0.27" lower_limit="-3.27" upper_limit="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK20 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6" lower_limit="90.23" upper_limit="97.36"/>
                    <measurement group_id="O2" value="92.7" lower_limit="88.68" upper_limit="95.61"/>
                    <measurement group_id="O3" value="1.88" lower_limit="-3.14" upper_limit="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK20 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="74.55" upper_limit="86.38"/>
                    <measurement group_id="O2" value="81.7" lower_limit="76.30" upper_limit="86.33"/>
                    <measurement group_id="O3" value="-0.73" lower_limit="-8.36" upper_limit="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK20 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="52.32" upper_limit="66.93"/>
                    <measurement group_id="O2" value="57.3" lower_limit="50.88" upper_limit="63.58"/>
                    <measurement group_id="O3" value="2.47" lower_limit="-6.93" upper_limit="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK24 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="84.34" upper_limit="93.67"/>
                    <measurement group_id="O2" value="85.4" lower_limit="80.32" upper_limit="89.54"/>
                    <measurement group_id="O3" value="4.31" lower_limit="-2.21" upper_limit="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK24 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="93.77" upper_limit="99.11"/>
                    <measurement group_id="O2" value="97.2" lower_limit="94.23" upper_limit="98.85"/>
                    <measurement group_id="O3" value="0.13" lower_limit="-3.65" upper_limit="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK24 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6" lower_limit="90.23" upper_limit="97.36"/>
                    <measurement group_id="O2" value="93.1" lower_limit="89.17" upper_limit="95.92"/>
                    <measurement group_id="O3" value="1.48" lower_limit="-3.51" upper_limit="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK24 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="78.16" upper_limit="89.18"/>
                    <measurement group_id="O2" value="83.3" lower_limit="78.08" upper_limit="87.77"/>
                    <measurement group_id="O3" value="0.91" lower_limit="-6.35" upper_limit="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK24 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" lower_limit="54.52" upper_limit="69.00"/>
                    <measurement group_id="O2" value="61.4" lower_limit="54.99" upper_limit="67.50"/>
                    <measurement group_id="O3" value="0.57" lower_limit="-8.71" upper_limit="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK36 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="380"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" lower_limit="86.59" upper_limit="95.63"/>
                    <measurement group_id="O2" value="90.9" lower_limit="86.25" upper_limit="94.33"/>
                    <measurement group_id="O3" value="1.06" lower_limit="-5.06" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK36 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="380"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="95.58" upper_limit="99.85"/>
                    <measurement group_id="O2" value="99.1" lower_limit="96.74" upper_limit="99.89"/>
                    <measurement group_id="O3" value="-0.33" lower_limit="-3.57" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK36 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="380"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" lower_limit="89.65" upper_limit="97.41"/>
                    <measurement group_id="O2" value="95.0" lower_limit="91.19" upper_limit="97.47"/>
                    <measurement group_id="O3" value="-0.57" lower_limit="-5.75" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK36 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="380"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.8" lower_limit="82.91" upper_limit="93.24"/>
                    <measurement group_id="O2" value="84.0" lower_limit="78.48" upper_limit="88.61"/>
                    <measurement group_id="O3" value="4.80" lower_limit="-2.39" upper_limit="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK36 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="380"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" lower_limit="57.96" upper_limit="73.12"/>
                    <measurement group_id="O2" value="64.4" lower_limit="57.65" upper_limit="70.72"/>
                    <measurement group_id="O3" value="1.45" lower_limit="-8.27" upper_limit="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK48 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8" lower_limit="80.42" upper_limit="93.18"/>
                    <measurement group_id="O2" value="86.8" lower_limit="80.52" upper_limit="91.63"/>
                    <measurement group_id="O3" value="1.03" lower_limit="-7.43" upper_limit="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK48 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="93.86" upper_limit="99.79"/>
                    <measurement group_id="O2" value="98.1" lower_limit="94.59" upper_limit="99.61"/>
                    <measurement group_id="O3" value="0.15" lower_limit="-4.41" upper_limit="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK48 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" lower_limit="87.86" upper_limit="97.52"/>
                    <measurement group_id="O2" value="91.2" lower_limit="85.67" upper_limit="95.10"/>
                    <measurement group_id="O3" value="2.72" lower_limit="-4.18" upper_limit="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK48 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" lower_limit="76.40" upper_limit="90.45"/>
                    <measurement group_id="O2" value="80.5" lower_limit="73.48" upper_limit="86.35"/>
                    <measurement group_id="O3" value="3.84" lower_limit="-5.59" upper_limit="12.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK48 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" lower_limit="59.38" upper_limit="77.02"/>
                    <measurement group_id="O2" value="61.6" lower_limit="53.60" upper_limit="69.23"/>
                    <measurement group_id="O3" value="7.06" lower_limit="-4.44" upper_limit="18.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK60 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="78.21" upper_limit="93.84"/>
                    <measurement group_id="O2" value="83.9" lower_limit="76.00" upper_limit="90.02"/>
                    <measurement group_id="O3" value="3.60" lower_limit="-6.97" upper_limit="13.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK60 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="89.43" upper_limit="99.22"/>
                    <measurement group_id="O2" value="95.0" lower_limit="89.35" upper_limit="98.13"/>
                    <measurement group_id="O3" value="1.29" lower_limit="-5.94" upper_limit="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK60 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="81.24" upper_limit="95.58"/>
                    <measurement group_id="O2" value="89.9" lower_limit="83.05" upper_limit="94.68"/>
                    <measurement group_id="O3" value="0.08" lower_limit="-9.42" upper_limit="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK60 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="72.38" upper_limit="90.09"/>
                    <measurement group_id="O2" value="74.8" lower_limit="66.01" upper_limit="82.30"/>
                    <measurement group_id="O3" value="7.71" lower_limit="-4.27" upper_limit="18.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK60 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="53.52" upper_limit="75.33"/>
                    <measurement group_id="O2" value="56.3" lower_limit="46.91" upper_limit="65.37"/>
                    <measurement group_id="O3" value="8.70" lower_limit="-5.19" upper_limit="21.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK72 IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="70.83" upper_limit="94.43"/>
                    <measurement group_id="O2" value="80.0" lower_limit="67.67" upper_limit="89.22"/>
                    <measurement group_id="O3" value="5.37" lower_limit="-10.7" upper_limit="19.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK72 PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="80.08" upper_limit="98.46"/>
                    <measurement group_id="O2" value="93.4" lower_limit="84.05" upper_limit="98.18"/>
                    <measurement group_id="O3" value="-0.76" lower_limit="-13.5" upper_limit="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK72 PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="70.83" upper_limit="94.43"/>
                    <measurement group_id="O2" value="88.5" lower_limit="77.78" upper_limit="95.26"/>
                    <measurement group_id="O3" value="-3.16" lower_limit="-18.1" upper_limit="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK72 PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" lower_limit="59.70" upper_limit="87.64"/>
                    <measurement group_id="O2" value="73.8" lower_limit="60.93" upper_limit="84.20"/>
                    <measurement group_id="O3" value="1.84" lower_limit="-15.8" upper_limit="17.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK72 PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="42.11" upper_limit="73.68"/>
                    <measurement group_id="O2" value="50.8" lower_limit="37.70" upper_limit="63.86"/>
                    <measurement group_id="O3" value="7.72" lower_limit="-11.7" upper_limit="26.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Mean Changes From Baseline in IGA Mod 2011 Between Cohorts at Each Time Point (LOCF) (ITT)</title>
        <description>IGA mod 2011 scale measures severity of the psoriasis on a five-point scale ranging from 0 (no disease, 'clear') to 4 ('very severe').</description>
        <time_frame>Baseline up to approximately 72 weeks</time_frame>
        <population>The number of patients across visits varied</population>
        <group_list>
          <group group_id="O1">
            <title>Cw6-positive AIN457 300 mg</title>
            <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cw6-negative AIN457 300 mg</title>
            <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Mean Changes From Baseline in IGA Mod 2011 Between Cohorts at Each Time Point (LOCF) (ITT)</title>
          <description>IGA mod 2011 scale measures severity of the psoriasis on a five-point scale ranging from 0 (no disease, 'clear') to 4 ('very severe').</description>
          <population>The number of patients across visits varied</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>W1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="16.08"/>
                    <measurement group_id="O2" value="-7.3" spread="17.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.4" spread="22.73"/>
                    <measurement group_id="O2" value="-21.6" spread="22.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.0" spread="25.45"/>
                    <measurement group_id="O2" value="-36.5" spread="27.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.6" spread="29.36"/>
                    <measurement group_id="O2" value="-49.5" spread="29.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71.2" spread="28.60"/>
                    <measurement group_id="O2" value="-71.2" spread="28.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.7" spread="27.31"/>
                    <measurement group_id="O2" value="-79.0" spread="25.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.1" spread="24.52"/>
                    <measurement group_id="O2" value="-83.3" spread="22.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.3" spread="24.26"/>
                    <measurement group_id="O2" value="-84.5" spread="23.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-86.2" spread="25.17"/>
                    <measurement group_id="O2" value="-84.1" spread="26.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-88.6" spread="22.34"/>
                    <measurement group_id="O2" value="-87.6" spread="23.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-86.2" spread="25.75"/>
                    <measurement group_id="O2" value="-84.9" spread="26.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.3" spread="28.44"/>
                    <measurement group_id="O2" value="-81.0" spread="26.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.1" spread="32.92"/>
                    <measurement group_id="O2" value="-75.8" spread="29.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Reach PASI 90 and 75 (ITT)</title>
        <description>Time in days to reach PASI scores of 90 and 75.</description>
        <time_frame>Baseline up to approximately 72 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cw6-positive AIN457 300 mg</title>
            <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cw6-negative AIN457 300 mg</title>
            <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Reach PASI 90 and 75 (ITT)</title>
          <description>Time in days to reach PASI scores of 90 and 75.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="30" upper_limit="89"/>
                    <measurement group_id="O2" value="58" lower_limit="55" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="22" upper_limit="57"/>
                    <measurement group_id="O2" value="29" lower_limit="22" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>difference between cohorts for PASI 90 using Kaplan-Meier estimate</non_inferiority_desc>
            <p_value>0.1295</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4470</p_value>
            <p_value_desc>difference between cohorts for PASI 75 using Kaplan-Meier estimate</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Dermatology Life Quality Index (DLQI) (LOCF) (FAS)</title>
        <description>The DLQI total score was calculated by summing the score of each domain resulting in a maximum of 30 and a minimum of 0. The higher the score, the more Quality of Life was impaired. Meaning of DLQI Scores: 0-1 = no effect at all on patient's life, 2-5 = small effect on patient's life, 6-10 = moderate effect on patient's life, 11-20= very large effect on patient's life, 21-30 = extremely large effect on patient's life. It was pre-specified that results would be presented for all patients, not by cohort</description>
        <time_frame>Baseline up to approximatly 72 weeks</time_frame>
        <population>Number of patients varied across visits. Both arms were combined because there is no clinical rationale to show a difference between the cohorts. Cw6 status does not have any impact on Quality of Life.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients in the Safety Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Dermatology Life Quality Index (DLQI) (LOCF) (FAS)</title>
          <description>The DLQI total score was calculated by summing the score of each domain resulting in a maximum of 30 and a minimum of 0. The higher the score, the more Quality of Life was impaired. Meaning of DLQI Scores: 0-1 = no effect at all on patient's life, 2-5 = small effect on patient's life, 6-10 = moderate effect on patient's life, 11-20= very large effect on patient's life, 21-30 = extremely large effect on patient's life. It was pre-specified that results would be presented for all patients, not by cohort</description>
          <population>Number of patients varied across visits. Both arms were combined because there is no clinical rationale to show a difference between the cohorts. Cw6 status does not have any impact on Quality of Life.</population>
          <units>numbers in a score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="420"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>At all time points</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Scores of HAD-A and HAD-D (Anxiety and Depression) (LOCF) (FAS)</title>
        <description>The Hospital Anxiety and Depression Scale (HADS) is a fourteen-item scale.. Seven of the items relate to anxiety and seven relate to depression. This outcome measure was specifically developed to avoid reliance on aspects of these conditions that are also common somatic symptoms of illness, for example fatigue and insomnia or hypersomnia. Calculations of scores: each of the 14 items was rated on a 4-point scale. All items except 7 and 10 were scored as Yes, definitely = 3, Yes, sometimes = 2, No, not much = 1, to No, not at all = 0. Items 7 and 10 were scored as Yes, definitely = 0 to No, not at all = 3 in the reverse order. The HADS consisted of two sub-scores: the HAD-A (anxiety) and HAD-D (depression); each sub-score ranged from 0 to 21 points; scores ≥11 = presence of anxious or depressive disorders; scores between 8-10 points = borderline abnormal, and scores of ≤7 = disorder was not present. It was pre-specified that results would be presented for all patients, not by cohort</description>
        <time_frame>Baseline up approximately 72 weeks</time_frame>
        <population>Number of patients varies by visit. Both arms were combined because there is no clinical rationale to show a difference between the cohorts. Cw6 status does not have any impact on anxiety and depression.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients in the Safety Set</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Scores of HAD-A and HAD-D (Anxiety and Depression) (LOCF) (FAS)</title>
          <description>The Hospital Anxiety and Depression Scale (HADS) is a fourteen-item scale.. Seven of the items relate to anxiety and seven relate to depression. This outcome measure was specifically developed to avoid reliance on aspects of these conditions that are also common somatic symptoms of illness, for example fatigue and insomnia or hypersomnia. Calculations of scores: each of the 14 items was rated on a 4-point scale. All items except 7 and 10 were scored as Yes, definitely = 3, Yes, sometimes = 2, No, not much = 1, to No, not at all = 0. Items 7 and 10 were scored as Yes, definitely = 0 to No, not at all = 3 in the reverse order. The HADS consisted of two sub-scores: the HAD-A (anxiety) and HAD-D (depression); each sub-score ranged from 0 to 21 points; scores ≥11 = presence of anxious or depressive disorders; scores between 8-10 points = borderline abnormal, and scores of ≤7 = disorder was not present. It was pre-specified that results would be presented for all patients, not by cohort</description>
          <population>Number of patients varies by visit. Both arms were combined because there is no clinical rationale to show a difference between the cohorts. Cw6 status does not have any impact on anxiety and depression.</population>
          <units>numbers on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>W16 Anxiety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W24 Anxiety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="420"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W48 Anxiety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W72 Anxiety</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16 Depression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W24 Depression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="420"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W48 Depression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W72 Depression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>All time points</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between the Hospital Anxiety and Depression Scale (HADS) and PASI (FAS)</title>
        <description>PASI score, HADS questionnaire correlation using Spearman rank correlation coefficient. It was pre-specified that results would be presented for all patients, not by cohort</description>
        <time_frame>Baseline up to approximately 72 weeks</time_frame>
        <population>Both arms were combined because there is no clinical rationale to show a difference between the cohorts. Cw6 status does not have any impact on anxiety and depression.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients in the Safety Set</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between the Hospital Anxiety and Depression Scale (HADS) and PASI (FAS)</title>
          <description>PASI score, HADS questionnaire correlation using Spearman rank correlation coefficient. It was pre-specified that results would be presented for all patients, not by cohort</description>
          <population>Both arms were combined because there is no clinical rationale to show a difference between the cohorts. Cw6 status does not have any impact on anxiety and depression.</population>
          <units>numbers on scores</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Body Mass Index (Safety Set)</title>
        <description>Change in Body mass index from baseline for patients with a value at baseline and the respective post-baseline visit</description>
        <time_frame>Baseline up to approximately 72 weeks</time_frame>
        <population>Number of patients varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Cw6-positive AIN457 300 mg</title>
            <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cw6-negative AIN457 300 mg</title>
            <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Body Mass Index (Safety Set)</title>
          <description>Change in Body mass index from baseline for patients with a value at baseline and the respective post-baseline visit</description>
          <population>Number of patients varied across visits</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="163"/>
                    <count group_id="O2" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.064" spread="0.7748"/>
                    <measurement group_id="O2" value="-0.047" spread="0.9905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.086" spread="1.0213"/>
                    <measurement group_id="O2" value="-0.071" spread="1.2260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.302" spread="1.3474"/>
                    <measurement group_id="O2" value="-0.052" spread="1.4991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.533" spread="1.8101"/>
                    <measurement group_id="O2" value="-0.015" spread="1.8982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Waist Circumference (Safety Set)</title>
        <description>Change in waist circumference from baseline for patients with a value at baseline and the respective post-baseline visit</description>
        <time_frame>Baseline up to approximately 72 weeks</time_frame>
        <population>Number of patients varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Cw6-positive AIN457 300 mg</title>
            <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cw6-negative AIN457 300 mg</title>
            <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Waist Circumference (Safety Set)</title>
          <description>Change in waist circumference from baseline for patients with a value at baseline and the respective post-baseline visit</description>
          <population>Number of patients varied across visits</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="3.147"/>
                    <measurement group_id="O2" value="-0.40" spread="3.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="3.689"/>
                    <measurement group_id="O2" value="-0.73" spread="4.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="4.596"/>
                    <measurement group_id="O2" value="-0.72" spread="5.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="4.583"/>
                    <measurement group_id="O2" value="-0.47" spread="4.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Weight (Safety Set)</title>
        <description>Change in weight from baseline for patients with a value at baseline and the respective post-baseline visit</description>
        <time_frame>Baseline up to approximately 72 weeks</time_frame>
        <population>Number of patients varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Cw6-positive AIN457 300 mg</title>
            <description>Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cw6-negative AIN457 300 mg</title>
            <description>Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Weight (Safety Set)</title>
          <description>Change in weight from baseline for patients with a value at baseline and the respective post-baseline visit</description>
          <population>Number of patients varied across visits</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="163"/>
                    <count group_id="O2" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="2.242"/>
                    <measurement group_id="O2" value="-0.13" spread="2.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="3.008"/>
                    <measurement group_id="O2" value="-0.21" spread="3.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="3.909"/>
                    <measurement group_id="O2" value="-0.15" spread="4.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="4.678"/>
                    <measurement group_id="O2" value="-0.05" spread="5.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 72 weeks</time_frame>
      <desc>Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events fields &quot;number of deaths resulting from adverse events&quot; all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cw6-Negative AIN457 300 mg</title>
          <description>Cw6-Negative AIN457 300 mg</description>
        </group>
        <group group_id="E2">
          <title>Cw6-Positive AIN457 300 mg</title>
          <description>Cw6-Positive AIN457 300 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Enthesopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Respiratory tract irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

